Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

Cited In for PubMed (Select 16027259)

1.

Functional changes in pulmonary arterial endothelial cells associated with BMPR2 mutations.

Wang H, Ji R, Meng J, Cui Q, Zou W, Li L, Wang G, Sun L, Li Z, Huo L, Fan Y, Penny DJ.

PLoS One. 2014 Sep 4;9(9):e106703. doi: 10.1371/journal.pone.0106703. eCollection 2014.

2.

BMP pathway regulation of and by macrophages.

Talati M, West J, Zaynagetdinov R, Hong CC, Han W, Blackwell T, Robinson L, Blackwell TS, Lane K.

PLoS One. 2014 Apr 8;9(4):e94119. doi: 10.1371/journal.pone.0094119. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e101543.

3.

Bone morphogenetic protein signaling protects against cerulein-induced pancreatic fibrosis.

Gao X, Cao Y, Staloch DA, Gonzales MA, Aronson JF, Chao C, Hellmich MR, Ko TC.

PLoS One. 2014 Feb 21;9(2):e89114. doi: 10.1371/journal.pone.0089114. eCollection 2014.

4.

Leukotrienes in pulmonary arterial hypertension.

Tian W, Jiang X, Sung YK, Qian J, Yuan K, Nicolls MR.

Immunol Res. 2014 May;58(2-3):387-93. doi: 10.1007/s12026-014-8492-5. Review.

5.

Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension.

Sawada H, Saito T, Nickel NP, Alastalo TP, Glotzbach JP, Chan R, Haghighat L, Fuchs G, Januszyk M, Cao A, Lai YJ, Perez Vde J, Kim YM, Wang L, Chen PI, Spiekerkoetter E, Mitani Y, Gurtner GC, Sarnow P, Rabinovitch M.

J Exp Med. 2014 Feb 10;211(2):263-80. doi: 10.1084/jem.20111741. Epub 2014 Jan 20.

6.

Deletion of the sequence encoding the tail domain of the bone morphogenetic protein type 2 receptor reveals a bone morphogenetic protein 7-specific gain of function.

Leyton PA, Beppu H, Pappas A, Martyn TM, Derwall M, Baron DM, Galdos R, Bloch DB, Bloch KD.

PLoS One. 2013 Oct 8;8(10):e76947. doi: 10.1371/journal.pone.0076947. eCollection 2013.

7.

Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension.

Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L, Rabinovitch M, Zamanian RT, Inayathullah M, Fridlib M, Rajadas J, Peters-Golden M, Voelkel NF, Nicolls MR.

Sci Transl Med. 2013 Aug 28;5(200):200ra117. doi: 10.1126/scitranslmed.3006674.

8.

Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.

Hadri L, Kratlian RG, Benard L, Maron BA, Dorfmüller P, Ladage D, Guignabert C, Ishikawa K, Aguero J, Ibanez B, Turnbull IC, Kohlbrenner E, Liang L, Zsebo K, Humbert M, Hulot JS, Kawase Y, Hajjar RJ, Leopold JA.

Circulation. 2013 Jul 30;128(5):512-23. doi: 10.1161/CIRCULATIONAHA.113.001585. Epub 2013 Jun 26.

9.

Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells.

Yang J, Li X, Li Y, Southwood M, Ye L, Long L, Al-Lamki RS, Morrell NW.

Am J Physiol Lung Cell Mol Physiol. 2013 Aug 15;305(4):L312-21. doi: 10.1152/ajplung.00054.2013. Epub 2013 Jun 14.

10.

Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation.

Chan SY, Loscalzo J.

Compr Physiol. 2011 Jan;1(1):123-39. doi: 10.1002/cphy.c090004. Review.

11.

A molecular mechanism for therapeutic effects of cGMP-elevating agents in pulmonary arterial hypertension.

Schwappacher R, Kilic A, Kojonazarov B, Lang M, Diep T, Zhuang S, Gawlowski T, Schermuly RT, Pfeifer A, Boss GR, Pilz RB.

J Biol Chem. 2013 Jun 7;288(23):16557-66. doi: 10.1074/jbc.M113.458729. Epub 2013 Apr 23.

12.

Protein Kinase C Inhibitors as Modulators of Vascular Function and their Application in Vascular Disease.

Khalil RA.

Pharmaceuticals (Basel). 2013;6(3):407-39. doi: 10.3390/ph6030407.

13.

SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension.

Han C, Hong KH, Kim YH, Kim MJ, Song C, Kim MJ, Kim SJ, Raizada MK, Oh SP.

Hypertension. 2013 May;61(5):1044-52. doi: 10.1161/HYPERTENSIONAHA.111.199158. Epub 2013 Mar 11.

14.

A process-based review of mouse models of pulmonary hypertension.

Das M, Fessel J, Tang H, West J.

Pulm Circ. 2012 Oct;2(4):415-33. doi: 10.4103/2045-8932.105030.

15.

Vascular remodeling in pulmonary hypertension.

Shimoda LA, Laurie SS.

J Mol Med (Berl). 2013 Mar;91(3):297-309. doi: 10.1007/s00109-013-0998-0. Epub 2013 Jan 19. Review.

16.

Molecular pathogenesis of pulmonary arterial hypertension.

Rabinovitch M.

J Clin Invest. 2012 Dec;122(12):4306-13. doi: 10.1172/JCI60658. Epub 2012 Dec 3. Review.

17.

Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice.

Mushaben EM, Hershey GK, Pauciulo MW, Nichols WC, Le Cras TD.

PLoS One. 2012;7(3):e32468. doi: 10.1371/journal.pone.0032468. Epub 2012 Mar 9.

18.

MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach.

Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, Hale A, Cottrill KA, Shaik RS, Waxman AB, Zhang YY, Maron BA, Hartner JC, Fujiwara Y, Orkin SH, Haley KJ, Barabási AL, Loscalzo J, Chan SY.

Circulation. 2012 Mar 27;125(12):1520-32. doi: 10.1161/CIRCULATIONAHA.111.060269. Epub 2012 Feb 27.

19.

A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene-Stewart L, Sung Y, Kraskauskas D, Farkas D, Conrad DH, Nicolls MR, Voelkel NF.

Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L977-91. doi: 10.1152/ajplung.00362.2011. Epub 2012 Feb 3. Review.

20.

BMPs and their clinical potentials.

Kim M, Choe S.

BMB Rep. 2011 Oct;44(10):619-34. doi: 10.5483/BMBRep.2011.44.10.619. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk